1031P - Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Bioethics, Legal, and Economic Issues
Presenter Keith Quintyne
Citation Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377
Authors K.I. Quintyne1, B. Woulfe2, A. Dee3, R. Gupta2
  • 1Community Oncology, National Cancer Control Programme (NCCP), D01 A3Y8 - Dublin/IE
  • 2Medical Oncology, Mid-Western Regional Hospital, 04048 - Limerick/IE
  • 3Department Of Public Health, HSE Mid-West, 04048 - Limerick/IE

Abstract

Background

Adjuvant treatment options for HER2-positive early-stage breast cancer (EBC) have expanded in recent years. Trastuzumab has been shown in several randomized controlled trials (RCTs) to offer significant survival advantage in patients with high-risk HER2-positive EBC. This study aimed to estimate cost-effectiveness of adjuvant trastuzumab therapy compared to standard chemotherapy alone in patients with HER2-positive EBC in Ireland.

Methods

A CEA was performed using a decision-tree model using estimate outcomes and costs over a 10-year period using a cohort of women with HER2-positive EBC, treated with or without 12 months of trastuzumab after adjuvant chemotherapy. These patients received ambulatory care in the Department of Medical Oncology (DoMO), University Hospital Limerick (UHL). Transition probabilities were derived from the cohort. Costs were estimated from the perspective of the Irish healthcare system. Both costs and outcomes were discounted by 5%. One-way sensitivity analysis was undertaken to assess the associated uncertainties in the expected output measures.

Results

In this study group, our model showed that adjuvant trastuzumab treatment in HER2-positive EBC, yield 8.54 quality-adjusted life-years (QALY) compared to adjuvant chemotherapy alone. Adjuvant trastuzumab treatment yielded an incremental cost-effectiveness ratio (ICER) of €42,801.62 per QALY.

Conclusions

It has been shown that for a 10-year time horizon, adjuvant trastuzumab is a cost-effective therapy for patients with HER2-positive, high-risk EBC (i.e. less that €45,000.00 threshold set in Republic of Ireland).

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.